Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Factors to consider when manufacturing CAR T-cells for patients with R/R multiple myeloma

Maximilian Merz • 10 Dec 2023
ASH 2023
Multiple Myeloma Antibodies CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Maximilian Merz, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, explores predictors for successful CAR-T cell production for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM). He mentions that chemotherapy within 6 months prior to apheresis is linked to poorer production, whereas bridging therapy with bispecific antibodies does not impact CAR-T manufacture, provided a washout period of 4-8 weeks. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria: Amgen, Takeda, BMS, Janssen, Stemline, Roche

More from Maximilian Merz

1:34
CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM
Maximilian Merz • 10 Dec 2023
1:52
Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM
Maximilian Merz • 10 Dec 2023
2:08
Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort
Maximilian Merz • 24 Mar 2022
1:52
Approval of cilta-cel by the FDA and its impact on the treatment landscape
Maximilian Merz • 24 Mar 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals